Objective: Differences in hospital case-mix have not been adequately accounted for in hospital volume and patient outcome studies in Japan. We aimed to examine whether differences may exist by investigating the distribution of patients' stage and age across designated cancer treatment hospitals of varying patient volume across Japan. Methods: We analyzed data of gastric, breast, colorectal, lung and liver cancer patients who were included in the national database of hospital-based cancer registries between 2008 and 2011. We investigated the association between hospital volume, cancer stage and patient age. Hospitals were classified into five groups according to patient volume. Results: In total, 676 713 patients met the inclusion criteria. The proportion of patients with earlystage (tumor-node-metastasis Stage 0 or I) cancer was higher among high-volume hospitals for all cancer types except small cell lung cancer. The proportion of older patients (age >75 years) was smaller among high-volume hospitals for all cancer types. The difference in the proportion of patients with early-stage cancers between very low-volume and very high-volume hospitals was greatest for non-small cell lung cancer (26.5% for very low and 43.5% for very high). This difference for the proportion of older patients was also greatest for non-small cell lung cancer (48.9% for very low and 30.3% for very high). Conclusions: We showed that the proportions of early-stage cancer patients and younger patients are greater in higher-volume hospitals compared with lower-volume hospitals in Japan. Researchers conducting volume-outcome studies and policymakers analyzing hospital performance should be cautious when making interhospital comparisons.
Introduction
The association between hospital volume and patient outcomes, such as mortality and length of hospital stay, is of considerable interest not only to patients and healthcare professionals but also to hospital administrators and policymakers, whose duty is to improve the care of patients and allocate appropriate resources to hospitals within community healthcare systems. Various studies on hospital volume and patient outcomes demonstrate that patients who receive cancer care or procedures at high-volume centers tend to perform better, both in short-and long-term outcomes (1) (2) (3) (4) (5) (6) . However, results of volumeoutcome studies must be interpreted with caution because they are prone to residual confounding, which is common when comparing hospital performance (7, 8) .
To make risk adjustments in mortality across hospitals, researchers often adjust for patient characteristics that may differ across institutions. For instance, Finks et al. (4) adjusted for patient age, sex, race, type of hospital admission (elective, urgent or emergency), comorbidities and socioeconomic status when comparing 30 day mortality for lung, esophageal, pancreatic and bladder cancer surgeries across hospitals of various hospital volume. Huo et al. (5) used propensity score matching to adjust for baseline mortality risk of metastatic melanoma patients across hospitals with varying caseloads. These adjustments are intended to address differences in case-mix of comorbid conditions and socioeconomic factors across various hospitals, and in doing so, conclude that the observed effects are not due to differences in these characteristics, but in some aspects of care that is provided in high-volume hospitals.
However, statistical adjustments are not perfect. Risk adjustments cannot fully compensate for interhospital variability when adjustments do not cover all important confounders, when sample size is small, or when characteristics of hospitals differ greatly (7, 8) . In Japan, cancer care hospitals range from small community hospitals, which treat various medical conditions; to medium-volume hospitals, which provide tertiary emergency services; and to larger university teaching hospitals and cancer research centers, where many clinical trials are conducted. Descriptive statistics from volume-outcome studies in Japan show that the mean age and stage of cancer patients are greater in low-volume hospitals compared with high-volume hospitals, supporting the idea that differences in patient population exist by hospital type and volume (9) (10) (11) (12) . Therefore, it is possible that highvolume hospitals are primarily treating younger and less-complex cases, whereas lower-volume hospitals are treating older patients, who may have more comorbidities, may be frailer, and may be more likely to develop complications. As yet, no study has investigated this issue. More fundamentally, we do not even know whether differences in basic patient characteristics, such as patient age and disease stage, exist by hospital volume across cancer care hospitals in Japan.
As a first step in understanding if these investigations should be pursued in the future so that more thorough risk adjustments, such as comorbidities and socioeconomic factors, should be done when making interhospital comparisons of cancer care performance in Japan, we studied the differences in the age and stage of gastric, breast, colorectal, lung and liver cancer patients among hospitals with different patient volumes, using hospital-based cancer registry data from 2008 to 2011.
Patients and methods

Database and study hospitals
We analyzed data of cancer patients included in the hospital-based cancer registry (HBCR) from 2008 to 2011. HBCR has been collecting demographic and diagnostic data of new cancer patients diagnosed, treated or followed up at designated cancer care hospitals (DCCHs) across Japan since 2007. They cover ∼70% of all cancer incidence in 2011 (13) . These hospitals are designated by the Ministry of Health, Labour and Welfare to provide specialized cancer care across communities in Japan, and they are required to submit their registry data to the National Cancer Center on an annual basis. The number of DCCHs that submitted data increased from 358 in 2008 to 370, 385 and 395 in 2009, 2010 and 2011, respectively. The registry database contains information on age and sex of patients as well as detailed clinical information, such as the following: clinical and pathological tumor-node-metastasis (TNM) stages; topology (site); histology codes of The International Classification of Diseases for Oncology, third edition (ICD-O-3); dates of diagnosis and treatment; and modalities used for the patients' first course of treatment. This information is collected by tumor registrars, who have completed training courses organized by the National Cancer Center, and subsequently undergoes data quality checks. Because some DCCHs do not receive a designation every year and may not have submitted registry data to the National Cancer Center for those years, we limited our analyses to hospitals that submitted registry data for all four years during the study period .
This study was approved by the institutional review board of the National Cancer Center, Japan, number 2013-151.
Target patients
We extracted the data of patients who were diagnosed with gastric cancer ( , lymphomas and hematological malignancies (9590-9989) and male breast cancer patients. We also excluded from our analysis patients who received endoscopic resection alone as their method of cancer treatment. Including these patients would have made hospitals with large caseloads of endoscopic resections appear to have a higher proportion of early-stage patients, while excluding these patients allowed us to obtain a conservative estimate for the relationship between hospital volume and cancer stage.
Definition of cancer stage and hospital classification
HBCR uses Union for International Cancer Control (UICC) TNM codes (UICC TNM classification of malignant tumors, 6th edition) to record cancer stages, except for liver cancer, which are staged using the Japanese staging standard (the General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edition, revised version) (14) . We used clinical stages of disease as the patients' final stage when pathological stages were not available.
We defined hospital volume by quintiles using the total number of patients registered from 2008 to 2011 for each type of cancer: very low volume (the lowest quintile), low volume, middle volume, high volume and very high volume (the highest quintile).
Statistical analyses
The associations between (i) hospital volume and the percentage of patients with Stage 0 or I disease and (ii) hospital volume and the percentage of patients aged >75 years, were evaluated using one-way analysis of variance (ANOVA). We used the Kruskal-Wallis test when the normality and equal variance assumptions of ANOVA did not hold. Patients with unknown stages were excluded from the first analysis ( proportion of patients with Stage 0 or I cancer). All tests for significance were two-tailed, with an α-value set at 0.05. Stata Figure 1 shows the flow chart for selecting the analytical dataset from the HBCR. While all 676 713 patients entered the analysis of hospital volume and patient age, 9425 patients (1.4%) were excluded from the volume-stage analysis due to unknown stages. Figure 2 shows the distributions of hospital volume across DCCHs. They were generally skewed to the right, primarily for breast cancer.
Demographic characteristics of patients in the analyses by hospital volume are shown in Table 1 . Breast cancer patients were the youngest (mean age ± standard deviation 60.7 ± 3.3 years) and non-small cell lung cancer patients were the oldest (70.9 ± 2.2 years).
Hospital volume and cancer stages
The associations between hospital volume and the proportion of patients with each cancer stage and early stage cancers (Stage 0 or I) according to cancer type are shown in Table 2 and Figure 3 . The proportion of patients with early stage cancer increased as hospital high-volume hospitals were greatest (17.0% difference) for non-small cell lung cancer.
Hospital volume and age
The associations between hospital volume and the proportion of patients aged >75 years (older patients) according to cancer type are shown in Table 3 and Figure 4 . For all cancer types, the proportion of patients aged >75 decreased as hospital volume increased. For gastric cancer, the proportion of older patients was 38.6% in very low-volume hospitals, but 29.2% in very high-volume hospitals. For breast cancer, the proportion was 25.4% for very low-volume hospitals and 10.4% for very high-volume hospitals. These figures were 39.0 and 30.0% for colorectal cancer, 48.9 and 30.3% for non-small cell lung cancer, 38.9 and 27.7% for small cell lung cancer and 38.3 and 31.7% for liver cancer. Differences in the proportion of older patients between very low-volume and very high-volume hospitals were greatest for non-small cell lung cancer (18.6% difference).
Discussion
Our study showed that higher-volume hospitals in Japan treat a larger proportion of early-stage gastric, breast, colorectal, liver and non-small cell lung cancer patients. In addition, high-volume hospitals treat a smaller proportion of patients aged >75 years with gastric, breast, colorectal, lung and liver cancers. Although we did not assess the overall health status of patients, including the presence of comorbidities, socioeconomic factors or lifestyle behaviors, our findings, which showed that high-volume hospitals are treating a greater proportion of younger and earlier-stage patients, raise the question that high-volume hospitals may be treating less-complex cases. Our findings have two major implications. First, they add to the difficulty in examining volume-outcome relationships in Japan. Several studies conducted in two regions of Japan have shown that patient outcomes are better in higher-volume hospitals than in lower-volume hospitals (9) (10) (11) (12) . This is consistent with reports from other countries, which showed that long-and/or short-term outcomes were superior at high-volume hospitals for various types of cancers, including gastric cancer (15) , colorectal cancer (6), esophageal cancer (16), breast cancer (3), lung cancer (1) and pancreatic cancer (17) . However, the presence of comorbidities and socioeconomic factors can confound the relationship between hospital volume and outcomes (18) . If our study findings are indicative of a general tendency among high-volume hospitals to treat less-complex cases than low-volume hospitals, what we have observed in volume-outcome studies in Japan can simply be explained by healthier patients having better outcomes.
Few studies have investigated the relationship between hospital volume and patient outcomes while accounting for a wide range of potentially confounding factors, including cancer stage, patient age, comorbidities and socioeconomic status. Zhan et al. (19) investigated the relationship between hospital volume and 30-day hospital mortality rate for Stage I-III colorectal cancer patients after adjusting for all of these factors. Zhan et al. showed that hospitals with higher surgical volume were treating a smaller proportion of patients who were at high risk of having poorer outcomes due to older age, advanced stage, multiple comorbidities and lower socioeconomic status compared with hospitals with lower surgical volume. Even after adjusting for hospital effects, these factors had a strong confounding effect on 30-day hospital mortality. Although we must wait for further studies to make any conclusions, a similar pattern of care may occur among cancer treatment hospitals in Japan.
The second implication of our findings is for patients and policymakers. DCCHs include community hospitals, which treat various other medical conditions aside from cancer, larger university teaching hospitals and high-volume cancer research centers. The roles of these hospitals are not clearly defined and may even overlap in many cases. Due to the lack of descriptive statistics, important policy questions remain unanswered. Should large university hospitals and cancer centers with high cancer patient volume focus their care on relatively younger patients who tend to have fewer medical complications and are more likely to be eligible for clinical trials? Or should they instead treat more complicated cases, such as patients with multiple comorbidities or frail elderly patients who may need multidisciplinary care? Some evidence suggests that older cancer patients benefit greatly by being treated at high-volume hospitals because these patients are at high risk of death (20) . Although information in this study is insufficient to make conclusions about the complexity of cases being treated at high-volume hospitals, our study findings can be used to initiate future discussion among clinicians, patients and policymakers concerning how cancer care should be coordinated across various hospitals.
Finally, it is important to note that our findings may reflect patient preference. Currently, no formal referral structure exists for cancer patients in Japan. The Japanese health insurance system scheme grants patients unrestricted access to tertiary and specialized care, allowing patients to be seen for the first time at cancer centers and university hospitals, without referrals from their local practitioners (21) . Aside from a small fee that hospitals can charge for a first patient visit without a referral, no restrictions are in place to stop patients from directly accessing specialists at high-volume hospitals. As younger and more mobile patients tend to choose hospitals more proactively than older patients or patients who have difficulty traveling (22) , the lack of restriction allows younger and mobile elderly patients to seek care at high-volume hospitals that are far, even if they have low-volume hospitals nearby (23) . Treatment-seeking behavior of cancer patients by stage is a topic that has not been investigated fully and will need to be addressed in future studies.
Our study has several limitations. First, our analyses only included data from DCCHs and may not be applicable to small community hospitals with different case-mix. However, we believe that our findings capture the majority of care practice patterns in Japan since the HBCR database covers ∼70% of all cancer incidence (13) . Second, our analysis is limited to five cancer types and should not be generalized to other cancers that are less common.
In conclusion, higher-volume designated cancer care hospitals in Japan tend to have a higher proportion of earlier-stage cancer patients for gastric, breast, colorectal, non-small cell lung and liver cancers. Moreover, higher-volume hospitals have a lower proportion of patients aged >75 years for these five cancer types. Our findings reinforce the importance of not making hospital performance comparisons in volume-outcome relationships using simple statistical adjustments. We hope that findings from this study are used to ignite further discussions among policymakers and various stakeholders on patient referral systems, and serve as one piece of evidence to help assign appropriate roles and resources to cancer treatment hospitals in Japan.
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